FUKOKU MUTUAL LIFE INSURANCE Co raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 57.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 203,143 shares of the company‚Äôs stock after buying an additional 74,000 shares during the quarter. Merck & Co., Inc. comprises about 1.8% of FUKOKU MUTUAL LIFE INSURANCE Co‚Äôs investment portfolio, making the stock its 16th biggest position. FUKOKU MUTUAL LIFE INSURANCE Co‚Äôs holdings in Merck & Co., Inc. were worth $12,331,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of MRK. Strategic Financial Services Inc raised its position in Merck & Co., Inc. by 1.0% in the second quarter. Strategic Financial Services Inc now owns 102,485 shares of the company‚Äôs stock valued at $6,221,000 after purchasing an additional 1,002 shares during the period. Signition LP purchased a new position in Merck & Co., Inc. in the second quarter valued at about $402,000. Cedar Hill Associates LLC raised its position in Merck & Co., Inc. by 64.3% in the second quarter. Cedar Hill Associates LLC now owns 6,121 shares of the company‚Äôs stock valued at $372,000 after purchasing an additional 2,395 shares during the period. Brighton Jones LLC raised its position in Merck & Co., Inc. by 9.6% in the second quarter. Brighton Jones LLC now owns 25,584 shares of the company‚Äôs stock valued at $1,553,000 after purchasing an additional 2,250 shares during the period. Finally, Blue Fin Capital Inc. raised its position in Merck & Co., Inc. by 4.7% in the second quarter. Blue Fin Capital Inc. now owns 30,415 shares of the company‚Äôs stock valued at $1,846,000 after purchasing an additional 1,357 shares during the period. 72.14% of the stock is currently owned by institutional investors.
Shares of MRK stock opened at $70.94 on Friday. The company has a market capitalization of $191.27 billion, a price-to-earnings ratio of 16.89, a P/E/G ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $71.57.Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the Zacks‚Äô consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to analysts‚Äô expectations of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The business‚Äôs revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 earnings per share. analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Stockholders of record on Monday, September 17th will be issued a dividend of $0.48 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.71%. Merck & Co., Inc.‚Äôs dividend payout ratio (DPR) is presently 48.24%.
MRK has been the topic of several research reports. TheStreet raised Merck & Co., Inc. from a ‚Äúc+‚ÄĚ rating to a ‚Äúb-‚ÄĚ rating in a research report on Friday, June 8th. Zacks Investment Research upgraded Merck & Co., Inc. from a ‚Äúhold‚ÄĚ rating to a ‚Äúbuy‚ÄĚ rating and set a $69.00 target price for the company in a research note on Thursday, June 7th. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the company a ‚Äúbuy‚ÄĚ rating in a research note on Thursday, August 23rd. SunTrust Banks restated a ‚Äúbuy‚ÄĚ rating and set a $77.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. Finally, Bank of America lifted their price target on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a ‚Äúbuy‚ÄĚ rating in a research note on Monday, July 30th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company‚Äôs stock. The company currently has a consensus rating of ‚ÄúBuy‚ÄĚ and an average target price of $68.55.
In related news, insider Sanat Chattopadhyay sold 29,208 shares of the business‚Äôs stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the sale, the insider now owns 70,675 shares of the company‚Äôs stock, valued at $4,608,010. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Kenneth C. Frazier sold 279,851 shares of the business‚Äôs stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $70.08, for a total value of $19,611,958.08. Following the sale, the chairman now directly owns 971,801 shares in the company, valued at approximately $68,103,814.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 649,510 shares of company stock worth $44,201,809. Corporate insiders own 0.32% of the company‚Äôs stock.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Read More: Return on Equity (ROE)
Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.